GENE ONLINE|News &
Opinion
Blog

AIDS
This One-Time Injection Could Cure AIDS
2022-06-21
FDA Allows Resumption of Gilead’s Lenacapavir AIDS Trials
2022-05-19
Gilead, Merck Unite to Contest ViiV’s Cabenuva with Long-Acting HIV Therapy
2021-03-16
Gilead Reports FDA-Approved HIV Therapy Demonstrates Long-Term Efficacy
2021-03-11
Gilead Aspires to Prolong Leadership in HIV Market, Launches Therapeutic Vaccine Quest with Gritstone
2021-02-03
Game-Changing Antiretroviral Regimen from ViiV Receives FDA Approval
2021-01-22
ViiV Healthcare’s Two Drug Regimen Shows Promising Results in HIV-1 Patients
2020-10-06
Merck Reports Higher Efficacy for Islatravir Doravirine Combo in Adults with HIV-1 Infection
2020-07-09
Long-Acting Cabotegravir Injection Performs Better as an HIV PrEP than Daily Pills
2020-05-22
Weekly Cover : Fosun and BioNTech Invest USD 135m for Covid-19 Vaccine
2020-03-19
Kainos Medicine’s New HIV Drug Kicks Off Phase III Trial in China
2020-03-05
The Scientists Strongly Condemned for the First Gene Editing Baby’s Birth in China
2018-11-27
US FDA Allows Phase II Clinical Trials for China’s anti-HIV Two-Drug Combo Therapy
2018-09-07
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top